Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII‐free emicizumab therapy

[1]  S. Meeks,et al.  Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status , 2021, Research and practice in thrombosis and haemostasis.

[2]  V. Jiménez‐Yuste,et al.  Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors , 2021, Expert review of hematology.

[3]  S. Lacroix-Desmazes,et al.  Acquired Hemophilia A in IgG4-Related Disease: Case Report, Immunopathogenic Study, and Review of the Literature , 2020, Frontiers in Immunology.

[4]  J. Blatny,et al.  The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. , 2020, Blood advances.

[5]  S. Corman,et al.  Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events , 2019, Journal of medical economics.

[6]  J. Oldenburg,et al.  The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[8]  C. Hay,et al.  The principal results of the International Immune Tolerance Study: a randomized dose comparison. , 2012, Blood.

[9]  R. d'Oiron,et al.  Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII‐specific T cells , 2011, Journal of thrombosis and haemostasis : JTH.

[10]  J. Vermylen,et al.  Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. , 1996, The Journal of clinical investigation.